BOPI 03 BR/2023 REPERTOIRE NUMERIQUE 29 (54) Early management and prevention of sepsis and sepsis-like syndromes. (72) LEWIN, Matthew R. (US) et CARTER, Rebecca (US) (73) OPHIREX, INC, 5643 Paradise Drive #2, CORTE MADERA, CA 94925 (US) (74) Cabinet BONNY & Associés, LAW FIRM, B.P. 869, YAOUNDE (CM). (57) The present invention relates to the early treatment, including pre-diagnosis treatment, of sepsis and acute inflammatory syndromes such as systemic inflammatory response syndrome (SIRS) by PLA2 and metalloprotease inhibitors to improve the performance of antibiotics and outcomes prior to and after confirmation of the diagnosis of sepsis and/or SIRS in a patient or subject. Additional embodiments include methods of treating sepsis, anthrax and severe acute respiratory syndrome coronavirus (SARS and SARS-CoV2) and related inflammatory syndromes and compositions, including pharmaceutical compositions and blood sample compositions. In further embodiments, the present invention is directed to embodiments which evidence that LY315920, LY333013 and related sPLA2 inhibitors are particularly effective COVID19/cytokine release syndrome therapeuticsprophylactics. In embodiments, the PLA2 inhibitor is varespladib (LY3 1 5920), methyl varespladib (LY3330I 3), AZD27 16-(R)-3-(5'-benzyl-2'- carbamoyl-[1,1'-biphenyl]-3-yI)-2-methylpropanoic acid- as a racemic mixture or separately, as the "R" enantiomer) and LY433771 ((9- [(phenyI)methyl]-5-carbamoylcarbazol-4-yl) oxyacetic acid), a pharmaceutical^ acceptable salt thereof or a mixture thereof. In embodiments, the metalloprotease inhibitor is Prinomastat, Batimastat, marimastat or vorinostat dosed alone or in combination with preferred sPLA2 inhibitors for the treatment of infection, inflammatory and wound conditions arising from various causes. Methods and compositions for achieving accelerated treatment of wounds and burns, anthrax metalloprotease toxin (lethal factor) driven complications, ARDS, neo-natal and pediatric acute respiratory distress syndrome (neonatal/pediatric ARDS), including meconium aspiration syndrome are also disclosed. Fig. 1 Consulter le mémoire ________________________________________ (11) 20855 (51) C08K 5/00 (2018.01); C08L 3/02 (2018.01); C08L 67/02 (2018.01) (21) 1202200156 - PCT/KR2020/014415 (22) 21/10/2020 (30) KR n° 10-2019-0130936 du 21/10/2019 (54) Renewable resin composition and product manufactured from same. (72) NHAN CHI, Ha Thuc (VN) et HWANG, Jiyoung (KP) (73) GREEN WHALE GLOBAL CO., LTD., (Nonhyeon-dong) 2F, Korea Construction Engineers Association Bldg., 650, Eonju-ro, Gangnam-gu, SEOUL 06098 (KR) (74) S.C.P AKKUM, AKKUM & Associates, n° 1777, Rue 6.261, Auditorium Jean Paul II, Quartier Mbankolo, B.P. 4966, YAOUNDE (CM). (57) Proposed are a renewable resin composition and a product manufactured therefrom, wherein the recyclable resin composition comprises: 100 parts by weight of cassava starch; 100 to 200 parts by weight of polybutylene succinate (PBS); 20 to 120 parts by weight of poly(butylene adipate-coterephthalate) (PBAT); and 10 to 40 parts by weight of a plasticizer. Consulter le mémoire ________________________________________ (11) 20856 (51) E04B 1/348 (2018.01); E04H 5/02 (2018.01) (21) 1202200171 - PCT/FR2020/051955 (22) 29/10/2020
RkJQdWJsaXNoZXIy MTM1NDc3MA==